原发耐药急性髓系白血病伴费城染色体阳性一例并文献复习
A Case of Philadelphia Chromosome-Positive Acute Myeloid Leukemia (Ph+AML) of Primary Drug Resistance and Relevant Literature Review
DOI: 10.12677/WJCR.2021.114016, PDF,   
作者: 王梦莹, 许 晗：青岛大学医学部，山东 青岛；青岛大学附属医院血液科，山东 青岛；冯献启*：青岛大学附属医院血液科，山东 青岛
关键词: 急性髓系白血病；费城染色体；原发耐药；Acute Myeloid Leukemia； Philadelphia Chromosome； Primary Drug Resistance
摘要: 费城染色体阳性急性髓系白血病(Ph+AML)是一种罕见的AML亚型，2016年修订的世界卫生组织(WTO)髓系恶性肿瘤将其归类为预后不良伴有遗传学异常的AML暂定型。Ph+AML是有别于慢性髓系白血病的一组高度复杂的异质性疾病，对化疗反应差，易复发，预后不佳，具有独特的临床和血液学特点。
Abstract: Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML), as a rare subtype of AML, is classified as provisional AML of poor prognosis accompanied with genetic abnormalities according to the 2016 revision of World Health Organization (WTO)-defined myeloid malignancy. Ph+AML is a group of highly complex heterogeneous diseases different from chronic myeloid leukemia (CML) with poor response to chemotherapy. It is characterized by easy recurrence, poor prognosis, and unique clinical and hematological features.
文章引用：王梦莹, 许晗, 冯献启. 原发耐药急性髓系白血病伴费城染色体阳性一例并文献复习[J]. 世界肿瘤研究, 2021, 11(4): 121-125. https://doi.org/10.12677/WJCR.2021.114016

参考文献

[1] Shao, X., et al. (2018) Primary Philadelphia Chromosome Positive Acute Myeloid Leukemia. Medicine, 97, e12949.
[Google Scholar] [CrossRef] 
[2] 岳志霞, 等. 3例费城染色体阳性急性髓系白血病临床和实验室分析[J]. 中国小儿血液与肿瘤杂志, 2011, 16(4): 182-185.
[3] Paietta, E., et al. (1998) Biologic Heterogeneity in Philadelphia Chromosome-Positive Acute Leukemia with Myeloid Morphology: The Eastern Cooperative Oncology Group Experience. Leukemia, 12, 1881-1885.
[Google Scholar] [CrossRef] [PubMed]
[4] Atfy, M., Al Azizi, N.M.A. and Elnaggar, A.M. (2011) Incidence of Philadelphia-Chromosome in Acute Myelogenous Leukemia and Biphenotypic Acute Leukemia Patients: And Its Role in Their Outcome. Leukemia Research, 35, 1339-1344.
[Google Scholar] [CrossRef] [PubMed]
[5] Goldman, J.M. and Melo, J.V. (2003) Chronic Myeloid Leukemia—Advances in Biology and New Approaches to Treatment. The New England Journal of Medicine, 349, 1451-1464.
[Google Scholar] [CrossRef] 
[6] Cortes, J. and O’Dwyer, M.E. (2004) Clonal Evolution in Chronic Myelogenous Leukemia. Hematology/Oncology Clinics of North America, 18, 671-684.
[Google Scholar] [CrossRef] [PubMed]
[7] Keung, Y., et al. (2004) Philadelphia Chromosome Positive Myelodysplastic Syndrome and Acute Myeloid Leukemia-Retrospective Study and Review of Literature. Leukemia Research, 28, 579-586.
[Google Scholar] [CrossRef] [PubMed]
[8] Brattas, M.K., et al. (2018) Philadelphia Chromosome Positive AML Arising from JAK2-Positive Myelofibrosis. Biomarker Research, 6, 33.
[Google Scholar] [CrossRef] [PubMed]
[9] Sasaki, K., et al. (2021) Prognostic Factors for Progression in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Complete Molecular Response within 3 Months of Therapy with Tyrosine Kinase Inhibitors. Cancer, 127, 2648-2656.
[Google Scholar] [CrossRef] [PubMed]
[10] Ottmann, O.G. (2002) A Phase 2 Study of Imatinib in Patients with Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoid Leukemias. Blood, 100, 1965-1971.
[Google Scholar] [CrossRef] [PubMed]
[11] Konoplev, S., et al. (2012) Molecular Characterization of de novo Philadelphia Chromosome-Positive Acute Myeloid Leukemia. Leukemia & Lymphoma, 54, 138-144.
[Google Scholar] [CrossRef] [PubMed]
[12] Neuendorff, N.R., et al. (2015) BCR-ABL1+ Acute Myeloid Leukemia: Clonal Selection of a BCR-ABL1-Subclone as a Cause of Refractory Disease with Nilotinib Treatment. Acta Haematologica, 133, 237-241.
[Google Scholar] [CrossRef] [PubMed]
[13] 童春容, 等. 4例t(9;22)和/或BCR-ABL异常急性髓性白血病的报告[C]//第五届中国肿瘤学术大会暨第七届海峡两岸肿瘤学术会议, 国际肿瘤细胞与基因治疗学会会议, 第二届中日肿瘤介入治疗学术会议论文集: 2008年卷. 石家庄, 2008.
[14] 费新红, 等. 12例Ph染色体和BCR-ABL阳性急性髓系白血病临床分析[J]. 中国实验血液学杂志, 2012, 20(3): 545-548.
[15] 蔡文治, 等. Ph/BCR-ABL阳性急性髓系白血病12例临床及实验室特征分析[J]. 中华血液学杂志, 2015, 36(5): 398-402.
[16] 郝李霞, 等. BCR-ABL阳性急性髓系白血病1例并文献复习[J]. 临床血液学杂志, 2020, 33(11): 791-793.

为你推荐